{"Abbreviation":"CPA","Aliases":["Androcur","Cyproteroneacetate","Cyproterone 17-O-acetate","Cyproteron acetate","Cyproteron-R acetate","Cyprostat","SH 714","Cyproterone 17alpha-acetate","SH-714","SH 80714"],"Biological Half-Life":"Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.","CAS":"427-51-0","CanonicalSMILES":"CC(=O)C1(CCC2C1(CCC3C2C=C(C4=CC(=O)C5CC5C34C)Cl)C)OC(=O)C","ChEBI":"CHEBI:50743","ChEMBL":"CHEMBL139835","ChemicalClasses":["steroid"],"Color/Form":"Crystals from diisopropyl ether","Decomposition":"When heated to decomposition it emits toxic fumes of /hydrogen chloride/.","Dosing Info":[],"Drug Indication":"For the palliative treatment of patients with advanced prostatic carcinoma.","Drug Warnings":"Direct hepatic toxicity, including jaundice, hepatitis and hepatic failure, has been observed in patients treated with Cyprostat. At dosages of 100 mg and above cases with fatal outcome have also been reported. Most reported fatal cases were in men with advanced prostatic cancer. Toxicity is dose-related and develops, usually, several months after treatment has begun. Liver function tests should be performed pre-treatment, regularly during treatment and whenever any symptoms or signs suggestive of hepatotoxicity occur. If hepatotoxicity is confirmed, Cyprostat should be withdrawn, unless the hepatotoxicity can be explained by another cause, eg metastatic disease, in which case Cyprostat should be continued only if the perceived benefit outweighs the risk.","DrugClasses":["hormone"],"European Community (EC) Number":"207-048-3","IUPACName":"[(1S,2S,3S,5R,11R,12S,15R,16S)-15-acetyl-9-chloro-2,16-dimethyl-6-oxo-15-pentacyclo[9.7.0.02,8.03,5.012,16]octadeca-7,9-dienyl] acetate","InChI":"InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1","InChIKey":"UWFYSQMTEOIJJG-FDTZYFLXSA-N","MeSH Pharmacological Classification":"Chemical substances or agents with contraceptive activity in males. Use for male contraceptive agents in general or for which there is no specific heading. (See all compounds classified as Contraceptive Agents, Male.)","Melting Point":"200-201","MolecularFormula":"C\u003csub\u003e24\u003c/sub\u003eH\u003csub\u003e29\u003c/sub\u003eClO\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"416.9 g/mol","Pharmacodynamics":"Cyproterone is an antiandrogen. It suppresses the actions of testosterone (and its metabolite dihydrotestosterone) on tissues. It acts by blocking androgen receptors which prevents androgens from binding to them and suppresses luteinizing hormone (which in turn reduces testosterone levels).","PubChemId":9880,"Record Description":["Cyproterone acetate is a steroid ester resulting from the formal condensation of the carboxy group of acetic acid with the 17-hydroxy group of cyproterone. It is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. It has a role as an androgen antagonist, a progestin and a geroprotector. It is a 20-oxo steroid, a 3-oxo-Delta(4) steroid, a chlorinated steroid, a steroid ester and an acetate ester. It is functionally related to a cyproterone.","An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.","Cyproterone Acetate is the acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.","CYPROTERONE ACETATE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications.","An agent with anti-androgen and progestational properties. It shows competitive binding with dihydrotestosterone at androgen receptor sites.","Cyproterone acetate is a steroid ester resulting from the formal condensation of the carboxy group of acetic acid with the 17-hydroxy group of cyproterone. It is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. It has a role as an androgen antagonist, a progestin and a geroprotector. It is a 20-oxo steroid, a 3-oxo-Delta(4) steroid, a chlorinated steroid, a steroid ester and an acetate ester. It is functionally related to a cyproterone."],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Cyproterone_acetate"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q426185"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB04839"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/9880"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.9496.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL139835"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50743"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=427-51-0"},{"name":"KEGG","url":"https://www.kegg.jp/entry/D01368"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/4KM2BN5JHF"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID5020366"}],"Solubility":"Very soluble in dichloromethane and acetone; soluble in methanol; sparingly soluble in ethanol.","Stability/Shelf Life":"Stable under recommended storage conditions.","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="116.432mm" version="1.2" viewBox="0 0 125.801 116.432" width="125.801mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="117.0" stroke="none" width="126.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="109.798" x2="109.788" y1="24.869" y2="40.109"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="109.789" x2="120.309" y1="38.701" y2="44.784"/>
                        
                <line x1="108.569" x2="119.088" y1="40.812" y2="46.895"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="120.309" x2="115.049" y1="44.784" y2="41.7425"/>
                <line class="hi" stroke="#FF0D0D" x1="119.088" x2="113.82849999999999" y1="46.895" y2="43.8535"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="109.788" x2="96.585" y1="40.109" y2="47.72"/>
                  
            <line class="bond" id="mol1bnd4" x1="96.585" x2="105.526" y1="47.72" y2="60.014"/>
                  
            <line class="bond" id="mol1bnd5" x1="105.526" x2="96.585" y1="60.014" y2="72.307"/>
                  
            <line class="bond" id="mol1bnd6" x1="96.585" x2="82.056" y1="72.307" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd7" x1="82.056" x2="82.056" y1="67.634" y2="52.394"/>
                  
            <line class="bond" id="mol1bnd8" x1="96.585" x2="82.056" y1="47.72" y2="52.394"/>
                  
            <line class="bond" id="mol1bnd9" x1="82.056" x2="68.848" y1="52.394" y2="44.774"/>
                  
            <line class="bond" id="mol1bnd10" x1="68.848" x2="55.64" y1="44.774" y2="52.394"/>
                  
            <line class="bond" id="mol1bnd11" x1="55.64" x2="55.64" y1="52.394" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd12" x1="55.64" x2="68.848" y1="67.634" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd13" x1="82.056" x2="68.848" y1="67.634" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd14" x1="68.848" x2="68.848" y1="75.254" y2="90.494"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="55.64" x2="68.848" y1="98.114" y2="90.494"/>
                        
                <line x1="55.64" x2="66.41" y1="95.299" y2="89.086"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="55.64" x2="42.432" y1="98.114" y2="90.494"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="29.224" x2="42.432" y1="98.114" y2="90.494"/>
                        
                <line x1="29.224" x2="39.994" y1="95.299" y2="89.086"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="29.224" x2="16.016" y1="98.114" y2="90.494"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="17.236" x2="6.707" y1="91.197" y2="97.279"/>
                        
                <line x1="16.016" x2="5.487" y1="89.086" y2="95.167"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.707000000000001" x2="11.9715" y1="97.279" y2="94.238"/>
                <line class="hi" stroke="#FF0D0D" x1="5.487" x2="10.7515" y1="95.167" y2="92.1265"/>
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="16.016" x2="16.016" y1="90.494" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd21" x1="16.016" x2="16.025" y1="75.254" y2="60.012"/>
                  
            <line class="bond" id="mol1bnd22" x1="16.025" x2="29.224" y1="60.012" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd23" x1="16.016" x2="29.224" y1="75.254" y2="67.634"/>
                  
            <line class="bond" id="mol1bnd24" x1="29.224" x2="42.432" y1="67.634" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd25" x1="55.64" x2="42.432" y1="67.634" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd26" x1="42.432" x2="42.432" y1="90.494" y2="75.254"/>
                  
            <line class="bond" id="mol1bnd27" x1="42.432" x2="42.432" y1="75.254" y2="60.014"/>
                  
            <line class="bond" id="mol1bnd28" x1="55.64" x2="55.64" y1="98.114" y2="109.414"/>
                  
            <line class="bond" id="mol1bnd29" x1="82.056" x2="83.669" y1="52.394" y2="37.239"/>
                  
            <line class="bond" id="mol1bnd30" x1="96.585" x2="90.039" y1="47.72" y2="32.947"/>
                  
            <line class="bond" id="mol1bnd31" x1="90.758" x2="97.416" y1="26.144" y2="17.015"/>
                  
            <g class="bond" id="mol1bnd32">
                        
                <line x1="96.586" x2="91.731" y1="18.152" y2="7.194"/>
                        
                <line x1="98.816" x2="93.96" y1="17.164" y2="6.206"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="91.731" x2="94.1585" y1="7.193999999999999" y2="12.673"/>
                <line class="hi" stroke="#FF0D0D" x1="93.96" x2="96.388" y1="6.2059999999999995" y2="11.685"/>
            </g>
                  
            <line class="bond" id="mol1bnd33" x1="97.416" x2="112.569" y1="17.015" y2="18.635"/>
                  
            <path class="atom" d="M125.241 47.735q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.733 -.0 1.233 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM121.377 47.735q.0 .922 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm3" stroke="none"/>
                  
            <path class="atom" d="M5.078 98.113q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM1.215 98.113q-.0 .923 .387 1.459q.393 .529 1.22 .529q.84 .0 1.221 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.453q-.381 -.523 -1.209 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" id="mol1atm18" stroke="none"/>
                  
            <path class="atom" d="M56.134 111.377q-.785 .0 -1.238 .53q-.452 .524 -.452 1.447q-.0 .911 .416 1.446q.423 .53 1.268 .53q.322 .0 .608 -.053q.291 -.06 .565 -.143v.536q-.274 .101 -.565 .148q-.292 .054 -.697 .054q-.744 .0 -1.25 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q-.0 -.744 .268 -1.31q.274 -.565 .803 -.881q.53 -.321 1.28 -.321q.78 -.0 1.352 .285l-.244 .524q-.227 -.101 -.506 -.184q-.274 -.084 -.608 -.084zM58.891 115.801h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm24" stroke="none"/>
                  
            <path class="atom" d="M90.695 29.325q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM86.831 29.325q.0 .923 .387 1.459q.393 .529 1.221 .529q.839 .0 1.22 -.529q.387 -.536 .387 -1.459q.0 -.929 -.387 -1.453q-.381 -.523 -1.208 -.523q-.834 -.0 -1.227 .523q-.393 .524 -.393 1.453z" id="mol1atm26" stroke="none"/>
                  
            <path class="atom" d="M93.501 3.078q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM89.638 3.078q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.386 -.536 .386 -1.459q.0 -.929 -.386 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" id="mol1atm28" stroke="none"/>
                
            <line class="hi" id="mol1bnd28" stroke="#1FF01F" x1="55.64" x2="55.64" y1="109.414" y2="103.76400000000001"/>
            <line class="hi" id="mol1bnd30" stroke="#FF0D0D" x1="90.039" x2="93.312" y1="32.947" y2="40.3335"/>
            <line class="hi" id="mol1bnd31" stroke="#FF0D0D" x1="90.758" x2="94.08699999999999" y1="26.144" y2="21.5795"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Androgen Antagonists; Antineoplastic Agents; Contraceptive Agents, Male; Progestational Hormones, Synthetic","Title":"Cyproterone acetate","UNII":"4KM2BN5JHF","Wikidata":"Q426185","XLogP":3.6}